Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01431248
Other study ID # PEACE
Secondary ID
Status Completed
Phase N/A
First received September 7, 2011
Last updated January 15, 2013
Start date September 2011
Est. completion date January 2013

Study information

Verified date January 2013
Source University of Oklahoma
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Preterm Premature Rupture of Membranes (PPROM) is treated with an antibiotic, erythromycin or azithromycin, to prolong pregnancy. Erythromycin is taken for several days and can result in stomach upset in some patients, causing them to stop taking the medication. Therefore, azithromycin is often prescribed instead. Azithromycin is usually taken only once and stomach upset is not seen or greatly reduced. The goal of this study is to see if there is a difference between the antibiotic (azithromycin) compared to the antibiotic (erythromycin) in prolonging pregnancy in patients with Preterm Premature Rupture of Membranes (PPROM). The working hypothesis is that there is no difference in the clinical effectiveness between antibiotic regimens containing te macrolides azithromycin and erythromycin for prolonging latency in PPROM.


Description:

The current standard regimen for PPROM patients between the gestational age of 24 0/7 and 32 0/7 weeks, is to administer ampicillin 2gm IV every 6hours for 48hrs followed by amoxicillin 250mg orally every 8 hours for 5 days, with erythromycin 250mg IV for 48hours followed by 500mg orally every 8hours for 5 days. Our study design would be a prospective randomized trial. Consented, eligible women will be randomized to receive ampicillin as above plus either azithromycin 1 gm orally at enrollment or erythromycin 250mg IV every 6 hours for 48hours followed by 500mg orally every 8hours for 5 days. Those who are unable to tolerate the 1gm of azithromycin within the first 30 minutes of administration, a 1000mg powder suspension will be given. In conjunction with standard protocol, a course of steroids for fetal lung maturity will be administered upon the treating staff's discretion, and all Group B Beta Streptococcus positive patients will be treated.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Pregnant women at least 18 years old

- Gestational age of 24 0/7 to 32 0/7 weeks

- Singleton gestation

- Randomization within 36 hours of rupture of membranes.

- Cervical dilation less than or equal to 4 cm.

Exclusion Criteria:

- Known lethal fetal anomaly

- Vaginal bleeding

- Maternal or fetal indication for delivery

- Diagnosis of chorioamnionitis on admission

- Cervical cerclage in place

- Placenta previa or other known placental anomalies

- Use of antibiotic therapy within 5 days.

- Allergy or other contraindications to erythromycin/azithromycin or steroid use.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Oklahoma Indiana University School of Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Time to delivery To compare the mean time to delivery, using azithromycin versus erythromycin to prolong latency in PPROM patients. The working hypothesis for this aim is that there is no difference in the clinical effectiveness between antibiotic regimens containing the macrolides azithromycin and erythromycin for prolonging latency in PPROM. 2 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04588220 - Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
Completed NCT02314728 - Cervical Ripening in Premature Rupture of Membranes N/A
Not yet recruiting NCT01152528 - Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery Phase 3
Completed NCT02702297 - Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes
Not yet recruiting NCT02635451 - The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes N/A
Completed NCT01266928 - Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study Phase 3
Active, not recruiting NCT04532021 - Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
Recruiting NCT02548013 - Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management N/A
Recruiting NCT01584323 - Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes N/A
Recruiting NCT00466128 - Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Phase 2
Terminated NCT00463736 - Magnesium Sulfate Versus Placebo for Tocolysis in PPROM N/A